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Objectives: To evaluate outcomes following implementation of a checklist with criteria for switching
from intravenous (iv) to oral antibiotics on unselected patients on two general medical wards.
Methods: During a 12 month intervention study, a printed checklist of criteria for switching on the third
day of iv treatment was placed in the medical charts. The decision to switch was left to the discretion
of the attending physician. Outcome parameters of a 4 month control phase before intervention were
compared with the equivalent 4 month period during the intervention phase to control for seasonal
confounding (before–after study; April to July of 2006 and 2007, respectively): 250 episodes (215
patients) during the intervention period were compared with the control group of 176 episodes (162
patients). The main outcome measure was the duration of iv therapy. Additionally, safety, adherence to
the checklist, reasons against switching patients and antibiotic cost were analysed during the whole
year of the intervention (n5698 episodes).
Results: In 38% (246/646) of episodes of continued iv antibiotic therapy, patients met all criteria for
switching to oral antibiotics on the third day, and 151/246 (61.4%) were switched. The number of days
of iv antibiotic treatment were reduced by 19% (95% conﬁdence interval 9%–29%, P50.001; 6.0–
5.0 days in median) with no increase in complications. The main reasons against switching were per-
sisting fever (41%, n5187) and absence of clinical improvement (41%, n5185).
Conclusions: On general medical wards, a checklist with bedside criteria for switching to oral antibiotics
can shorten the duration of iv therapy without any negative effect on treatment outcome. The criteria were
successfully applied to all patients on the wards, independently of the indication (empirical or directed
treatment), the type of (presumed) infection, the underlying disease or the group of antibiotics being used.
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Introduction
The appropriate use of antimicrobial agents is crucial for
patients’ safety and public health,
1–5 particularly in view of
increasing drug resistance.
6 Hence, antimicrobial stewardship
programmes were developed as an essential ﬁeld of work for
infectious diseases (ID) specialists
7 with the goal of optimizing
clinical outcomes and minimizing the unintended consequences
of antimicrobial use, i.e. toxicity, the selection of pathogenic
organisms, emergence of resistance and high costs. The adoption
of antimicrobial stewardship programme activities has, therefore,
recently been advocated.
8 Nevertheless, the best strategies of
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9
One way of optimizing antibiotic use is to switch earlier from
intravenous (iv) to oral therapy, with the following advantages:
(i) beneﬁts to the patient, (ii) lower costs and (iii) reduced work-
load, e.g. reduced incidence of catheter-related infections, a
shorter length of hospital stay, a reduction in costs and an
associated reduction in workload without sacriﬁcing patient
safety.
10–18 Most iv antibiotics are more expensive than oral for-
mulations, and the costs of preparing and administering are
additional:
12 Indirect costs have been estimated to add from
13% to 113% to the costs of the drugs themselves.
19
The optimal time for switching to oral antibiotics is on days
2–4 of iv therapy, when the culture results and the initial clini-
cal course allow a reassessment of the treatment plan.
18,20–23
This reassessment is often neglected due to time constraints,
change of staff, unwillingness to change the mode of therapy in
an improving patient or insufﬁcient training.
24
Most studies on switching the mode of therapy have so far
been restricted to speciﬁc antibiotics
25–29 or medical conditions,
e.g. community-acquired pneumonia (CAP).
11,15,30–34 Af e w
studies have evaluated the criteria for switching from iv
antibiotics in a general population of medical patients
(Table 1).
12–14,16,17,35,36 However, the before–after studies were
not controlled for seasonal confounding,
12,14,17,36 and others
were limited to speciﬁc conditions
16 or to community-acquired
infections,
14,16 which hampers generalization to general medical
ward patients. Only two studies
12,13 provided information about
the reason for not switching to oral antibiotics.
We performed a before–after study with the goal to assess
the effect of an adapted published checklist
14,35 for physicians to
follow with respect to switching from iv to oral antibiotics in a
population of unselected, hospitalized patients on general
medical wards.
Patients and methods
Setting
The University Hospital Basel is a 780 bed tertiary care centre
serving  27000 admissions annually. The study was conducted on
two general internal medicine wards with  2500 admissions yearly
and annual antibiotic costs of about E300000.
Seven interns and residents with two senior physicians were in
charge of the two study wards on weekdays. On weekends, only two
interns or residents of the same team were in charge, with a senior
physician on call. An ID service was available at all hours.
The study was approved by the Ethics Committee of the Cantons
Basel-Stadt and Basel-Land (EKBB, Nr 126/06), which waived the
patient consent, since the study was part of a quality improvement
project.
Study population
All adults who were receiving iv antibiotics at the time of the study
were enrolled at the moment they were admitted to one of the study
wards. We excluded patients who were referred to the wards with iv
antibiotic treatment that had already lasted longer than 3 days,
patients on iv antibiotics who were transferred to other wards or
hospitals before the third day of treatment and patients who were
receiving prophylactic iv antibiotics.
Study design
The study was a before–after design study with an a priori deﬁned
time frame consisting of a 4 month control phase from 1 April 2006
through 31 July 2006 and an intervention phase from 1 April 2007
through 31 July 2007. To eliminate seasonal confounding, only
these 4 months were compared although the intervention was per-
formed during 1 year (1 August 2006 through 31 July 2007).
All patients were consecutively screened for enrolment. The
patients in the control phase were enrolled retrospectively using the
same criteria as for patients during the intervention phase.
Intervention
The intervention consisted of a printed checklist of criteria for
switching to oral antibiotics, adapted from Laing et al.
14 and Senn
et al.
35 (Figure 1). The checklist was placed in the patient’s chart.
On day 3 of iv antibiotic therapy, the physician in charge of the
patient was to complete the checklist and make a decision on the
basis of the checklist criteria about whether to switch to oral anti-
biotics. The protocol allowed the physician to complete the checklist
before the third day if switching to oral antibiotics. The ﬁnal
decision to switch to oral antibiotics, however, was left to the dis-
cretion of the treating physician.
If the reason for not switching to oral antibiotics was only the
patient’s inability to swallow tablets or ﬂuids or was a presumed
impairment in gastrointestinal absorption, a clinical pharmacist was
consulted to recommend other alternatives to iv therapy if possible.
When a physician did not switch a patient to oral antibiotics
despite the patient meeting all checklist criteria for doing so, he was
asked to indicate the reason in a free text box on the checklist.
Otherwise, there were no additional interventions by, or formal consul-
tations with, the study team. If a physician did not complete the check-
list by the end of the third day on iv therapy, he was asked to complete
the checklist with respect to the target day indicated on the checklist.
We deﬁned an episode as one uninterrupted course of antibiotic
treatment. The primary antibiotic was deﬁned as the iv antibiotic
that was applied for the longest duration.
Outcome parameters
The primary endpoint was the duration of iv therapy in days.
Secondary endpoints were the total number of times iv antibiotics
were administered during an episode of treatment and the associated
workload for nurses, the length of hospital stay, the costs and con-
sumption of the antibiotics and the incidence of complications
during iv therapy, i.e. phlebitis. We used the following indicators
for assessing the safety and efﬁcacy of the antibiotic treatment
regimen: re-initiation of iv antibiotic treatment, in-hospital mortality
and readmissions within 90 days of discharge.
The safety of the intervention, the adherence to the checklist’s
criteria and the reasons for physicians not switching patients were
analysed over the entire year of the intervention (1 August 2006 to
31 July 2007). The antibiotic consumption in ‘deﬁned daily doses’
(DDD) and costs were compared with those in the 2 years before
the start of the intervention and with the year after the stop of the
intervention.
Baseline assessment
The baseline assessment consisted of demographic data, the Charlson
Co-morbidity Index
37,38 and the presumed or documented ID.
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189Table 1. Summary comparison of previously published articles on ‘switch’ criteria on medical wards
Authors (in chronological order)
Ahkee et al.
13 Laing et al.
14 Sevinc et al.
12
von Gunten
et al.
16
Vogtla ¨nder
et al.
36 Senn et al.
35
McLaughlin
et al.
17
Mertz et al.
(current study)
Study design no comparison before–after
a before–after pilot study,
randomized
before–after randomized before–after before–after
Type of intervention study team guideline guideline pharmacist guideline study team guideline guideline
Duration of intervention 6 months 2 2 months
a 2 months 6 weeks 3 months 5 months 2 4 weeks 12 months
b
Patient population (C/I) 0/655 111/113
a/103
a 230/182 26/29 247/250 125/126 118/107
a/93
a 698
b; 176/250
Population constraints none included only patients
with CA infection
none limited to
speciﬁc
diagnoses
c
none intervention on
weekdays only
none none
Reasons for not
switching to oral
antibiotic
provided not provided provided not provided not provided not provided not provided provided
Duration of iv-Rx (C/I) 3 days 4.4/3.7 days
d 6/4 days
d (iv to
oral switch)
5/5.5 days
e 21.6 days
d iv to
oral switch
214%
e to
‘modiﬁcation’ of
iv-Rx
3/2 days
d 6/5 days
d (219%)
Percentage of patients
switched/within
number of days
40%/7 days 28%/3 days 23%/no time
limit
not provided not provided 64%/no time limit 73%/no time
limit
30%/3 days
Outcome measure relapse readmission
e,
mortality
e
readmission
e not provided not provided mortality
e not provided relapse
e,
readmission
e,
mortality
e
Cost/savings not provided not provided estimated savings per
patient
not provided not provided savings per
patient
workload and
antibiotic costs
CA, community-acquired; iv-Rx, treatment with iv antibiotics; C/I, control group/intervention group.
Search terms: switch, oral antibiotics, antibiotic stewardship and antimicrobial stewardship.
aOne control group and two groups after implementation of the intervention.
bn¼698, number of patients in which the intervention was performed (12 months); n¼176/250, number of patients in the control and intervention groups for statistical analysis (4 months per group).
cPopulation constricted to the following diagnoses: pneumonia, urinary tract infection, gastro-enteritis or skin and soft tissue infection.
dStatistical signiﬁcant difference between groups (if applicable).
eNo statistical signiﬁcant difference between groups (if applicable).
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191Statistical analysis
We analysed the primary endpoint using the ﬁrst treatment episode
for each patient only. In a secondary analysis, we analysed all treat-
ment episodes for all patients and corrected the standard errors for
the correlation of treatment durations in patients who received more
than one treatment episode.
Because the primary outcome measure showed a log normal dis-
tribution, we performed statistical analyses on the log data. For the
primary analysis, we ﬁtted a univariate and a multivariate adjusted
linear regression model for the log-transformed response and used
treatment as covariate. For the secondary analysis involving all treat-
ment episodes, we used generalized estimating equations (the GEE
approach)
39 on the log-transformed response using the robust
method to correct the conﬁdence intervals (CIs) and P values for
the within-patient correlation.
The effect estimates from both the linear models and the
GEE models were ﬁnally back-transformed to the original scale.
The back-transformed effect estimate corresponds to the ratio of
the median antibiotic treatment duration in the control group to the
median antibiotic treatment duration in the intervention group. We
used R statistical software, version 2.5.1, to ﬁt these models and for
inferential statistics.
To compare differences in the distribution of baseline character-
istics between patients who were enrolled in the control phase and
patients who were enrolled in the interventional phase, we used the x
2
test for binary data and the Mann–Whitney U-test or log-rank test for
continuous data (SPSS 15.0 software, SPSS Inc., Chicago, IL, USA).
All analyses are reported with 95% CIs. Tests with a two-sided
P value ,5% were regarded as signiﬁcant.
Results
Patient populations
For detailed analysis, a total of 250 iv antibiotic treatment epi-
sodes in 215 patients during the intervention phase were
compared with 176 episodes in 162 patients during the control
phase. For primary analysis, only the ﬁrst episode per patient
was analysed. For statistical analysis, all episodes were included.
Potentially eligible patients who were excluded are shown in
Figure 2.
To assess the safety of the intervention, the adherence to the
checklist’s criteria and the reasons for physicians not switching
patients, all patients enrolled over the entire year of the interven-
tion were analysed (n¼698 episodes, August 2006 to July
2007).
Analysis of checklists
All of the 698 checklists that were distributed from 1 August
2006 through 31 July 2007 were retrieved. Of these, 546 (78%)
were completed on the target day for switching to oral anti-
biotics or earlier. In 52/698 episodes (7.4%), antibiotic treatment
was stopped and in 646/698 episodes (92.6%), antibiotic treat-
ment was continued (Table 2). A switch to oral antibiotics was
decided in 191/646 episodes (29.6%). Therefore, iv therapy was
discontinued on the third day of iv therapy—either by stopping
or switching to oral therapy—in 243/698 (34.8%) episodes.
During the 4 month intervention phase, the subgroup of patients
with lower respiratory tract infections (n¼72) were switched
more often to oral antibiotics (rate of 42%).
In 38% (246/646) of the episodes of continued iv antibiotic
therapy, patients met all criteria for switching to oral antibiotics
on the third day; 151/246 (61.4%) of these were actually
switched on the third day. The most frequent reasons indicated
for not switching to oral antibiotics in the remaining cases
(available in 74/95 cases) are summarized in Table 2. The phys-
icians in charge of the study wards adhered increasingly to our
guideline. In the ﬁrst months of the intervention (August to
October), adherence to the checklist was 48%; this rate increased
continuously to 68.7%.
Control phase (April to July 2006)
Episodes of iv antibiotic therapy
n = 209
Patient not on the study wards after
48–72 h of iv antibiotic therapy
n = 32
Episodes that meet
study criteria
n = 176
Prophylactic iv antibiotics
n = 1
Not first treatment episode for patient
n = 14
First episodes that meet
study criteria
n = 162
Intervention phase (April to July 2007)
Episodes of iv antibiotic therapy
n = 288
Patient not on the study wards after
48–72 h of iv antibiotic therapy
n = 31
Prophylactic iv antibiotics
n = 7
Episodes that meet
study criteria
n = 250
Not first treatment episode for patienta
n = 35 
First episodes that meet
study criteria
n = 215 
Figure 2. Patient populations in the control and intervention phases.
aThree of these episodes were excluded because these patients had already been included
in the control phase.
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meet all the criteria, but with no negative consequences; among
those were 16 (14.2%) of the 113 neutropenic patients.
Patients’ characteristics in the control
and intervention phase
The patients in the two study phases were comparable with
respect to gender, age, co-morbidities, C-reactive protein con-
centration and underlying presumed or documented infection
(Table 3).
At the beginning of the intervention, there was an initial
increase in the rate of ID consultations requested by ward phys-
icians (from August to October 2006 it was 34.7% compared
with 23.5% in the control phase from April to July 2006). Later
in the intervention phase, the rate decreased (27.4% from April
to July 2007).
Duration of antibiotic treatment and outcome of treatment
Comparing all ﬁrst episodes of patients receiving iv antibiotics
in the 4 month control phase with the 4 month intervention
phase at the end of the intervention—including patients not
qualifying for early switch—the median duration of iv antibiotic
treatment was reduced from 6.0 to 5.0 days (Table 4). The
unadjusted, relative reduction in median days of iv antibiotic
treatment was 16% (95% CI 4%–26%, P¼0.01) and 19%
(9%–29%, P¼0.001) after adjusting for age, gender, Charlson
Co-morbidity Index score, presence of malignancy and consul-
tations with ID specialists. Stratiﬁed by group of infection
(Table 3), there was a reduction of the median duration of iv
therapy in all subgroups except for endocarditis, infections of
bones or joints, urinary tract infections and enteritis/colitis. The
reduction was statistically signiﬁcant for lower respiratory tract
infections only (6.25–4.5 days in median, P¼0.002).
The Kaplan–Meier curve (Figure 3) illustrates that the
impact of earlier switching to oral antibiotics on the duration of
iv therapy was observed primarily up to the ninth day of anti-
biotic iv therapy, up to which time the difference between the
control and intervention groups continues to increase.
The increase in days of oral treatment and the decrease in
length of stay were not statistically signiﬁcant. Nevertheless,
there was a trend towards a shorter overall duration of antibiotic
treatment from 9.0 to 8.0 days (P¼0.100).
There was no signiﬁcant difference in the frequency of
restarting iv therapy, complications associated with the iv line,
mortality rate or readmission rate. All deaths that were due to ID
Table 2. Analysis of 646 checklists completed between 1 August 2006 and 31 July 2007
indicating continued antibiotic treatment after 48–72 h
Episodes switched after 48–72 h
yes (n¼191,
29.6%)
no (n¼455,
70.4%)
n % n %
Indications
documented infection 142 74.3 291 64.0
empirical treatment 49 25.7 164 36.0
Reasons indicated for not switching to oral therapy
a
not afebrile .24 h 16 8.4 187 41.1
no clinical improvement 10 5.2 185 40.7
oral administration of ﬂuids not feasible 1 0.5 26 5.7
oral administration of tablets not feasible 3 1.6 38 8.4
haematological malignancies or neutropenia 16 8.4 97 21.3
infections with strict iv indication
a 4 2.1 94 20.7
abscess without incisions, severe soft tissue infection,
osteomyelitis, septic arthritis
3 1.6 61 13.4
CNS infections, Staphylococcus aureus bacteraemia 0 0 24 5.3
endocarditis or intravascular infection 1 0.5 20 4.4
Impaired gastrointestinal absorption 2 1.0 26 5.7
Other exclusion criteria for oral therapy
b 1 0.5 94 20.7
aMore than one reason could be checked per patient as applicable.
bFor 74 patients, ‘Other exclusion criteria’ was the only criterion checked on the checklist for not switching to
oral antibiotics. Of these other criteria, the most frequently mentioned reasons were: diagnoses that were
thought to require iv therapy (n¼15, 16.0%); the (presumed) absence of an alternative oral therapy (n¼12,
12.7%); a senior attending physician’s decision to not follow the checklist (n¼11, 11.7%); patients on immuno-
suppressive therapy (n¼9, 9.6%); administrative problem related to target date occurring on a weekend or other
organizational issues (n¼8, 8.5%); the physician’s waiting for the ward round or additional results (n¼7, 7.4%)
and the physician in charge was unsure about the situation (n¼7, 7.4%).
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year of the intervention, only 2/698 (0.3%, or 1.0% of patients
who were switched to oral antibiotics according to our guide-
lines) failed on oral therapy. One patient with pyelonephritis
developed neuropsychiatric side effects related to oral ciproﬂox-
acin. Another patient with E. coli sepsis who was switched to
oral ciproﬂoxacin developed a fever again: further follow-up of
the patient revealed the presence of multiple liver abscesses.
Both patients recovered after continued iv therapy.
Workload and antibiotic costs and consumption
The total number of applications of iv antibiotics per patient
was reduced by 3 (a median of 15–12, adjusted relative
reduction of 25%) (11%–36%, P,0.001). A total of 698
patients received iv antibiotics over the 1 year intervention.
Because one application of iv antibiotics takes a mean of 10 min
[according to the standardized system of workload measure
‘Leistungserfassung in der Pﬂege’ (LEP), LEP AG], the esti-
mated total reduction in nurses’ workload was 350 h/year, equal
to 2 month’s salary for a nurse (E5438).
The total costs for antibiotics on the two study wards in the
years before the intervention were E240724 (August 2004 to July
2005) and E280706 (August 2005 to July 2006). During the year
of the intervention, there was a reduction of E13596 (August
2006 to July 2007) to E267110. The decrease in costs was
achieved primarily during the winter months, i.e. from November
2006 to March 2007. The year after the study (August 2007 to
July 2008), the costs decreased again by E23685 to E243425.
The highest consumption of oral antibiotics was achieved in
the year of the intervention (28.44 DDD/100 bed days) when com-
pared with 21.5 and 27.0 DDD/100 bed days in the 2 years before
the study and 27.2 DDD/100 bed days in the year after the study.
The most frequently used antibiotic in our hospital,
amoxicillin/clavulanate is available in iv and oral forms. The
overall consumption decreased by 4.7% in the study year,
although there was a 10.9% increase in the consumption of oral
amoxicillin/clavulanate.
Discussion
With a printed checklist available at the patient’s bedside as a
reminder of the criteria for switching from iv to oral antibiotics,
we signiﬁcantly reduced the duration of iv antibiotic therapy
without an increase in complications in unselected patients on
medical wards. This reduction in treatment duration was associ-
ated with a drop in the workload and the costs of antibiotics. We
Table 3. Statistical analysis of patient characteristics with ﬁrst episode of antibiotic treatment
Patient characteristic
Control phase (1 April 2006 to
31 July 2006) n¼162
Intervention phase (1 April 2007 to
31 July 2007) n¼215
P
value
a
Female gender, n (%) 73 (45.1) 84 (39.1) 0.243
Age, median (IQR) 66 (58–77) 67 (55–78) 0.950
Highest C-reactive protein value within 72 h after
initiation of antibiotic treatment, median (IQR)
151 (89–232) 144 (80–226) 0.564
Charlson Co-morbidity Index, median (IQR) 2 (1–5) 2 (1–4) 0.301
Malignancy, n (%) 54 (33.3) 87 (40.5) 0.157
Diabetes mellitus, n (%) 42 (25.9) 48 (22.3) 0.417
HIV positive, n (%) 3 (1.9) 10 (4.7) 0.140
Presumed or documented ID that were treated with iv
antibiotics, n (%)
lower respiratory infection 53 (32.7) 68 (31.6) 0.823
urinary tract infection 23 (14.2) 36 (16.7) 0.500
intra-abdominal infections
b 22 (13.6) 33 (15.3) 0.630
fever/SIRS of unknown focus 18 (11.1) 20 (9.3) 0.564
skin and soft tissue infections 10 (6.2) 19 (8.8) 0.337
fever in neutropenia 10 (6.2) 12 (5.6) 0.808
infections of bones or joints 10 (6.2) 8 (3.7) 0.269
enteritis or colitis 3 (1.9) 3 (1.4) 0.726
endocarditis 2 (1.2) 3 (1.4) 0.893
CNS infection 4 (2.5) 3 (1.4) 0.445
other infections 7 (4.3) 10 (4.7) 0.878
Consultation by ID specialist 38 (23.5) 59 (27.4) 0.367
ID, infectious diseases; IQR, interquartile range; SIRS, systemic inﬂammatory response syndrome.
aDifferences between groups using the Mann–Whitney U-test for non-categorical data and the x
2 test for categorical data.
bIncludes all (presumed) infections in the abdomen except enteritis and colitis.
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194found that the most frequent switch criteria not met were the
absence of clinical improvement or no abatement of fever.
Effectiveness of using the checklist
The checklist proved to be an effective method for reducing the
median duration of iv therapy from 6.0 to 5.0 days (219%),
which is comparable to results in other related studies (Table 1).
The difference was even more signiﬁcant if only the ﬁrst
episode of iv antibiotic treatment was being analysed. The
overall rate of switching patients to oral antibiotics on the third
day of iv therapy was 30%, which was comparable to results
noted by Laing et al.
14 We chose the third day of treatment as
the primary day of the intervention, because at that time the
culture results and the initial clinical course allow a
reassessment of the treating plan.
18,20–23 Nevertheless, many
patients were switched earlier according to our criteria.
The effect of the checklist on the duration of iv therapy was
probably diluted, because the analysis contained all episodes,
including those not fulﬁlling the switch criteria and patients
with infections with strict indication for iv treatment. The effect
would have been more notable if only patients fulﬁlling all
switch criteria on the third day of iv therapy in the two groups
were compared. However, this was not the aim of our study, and
a retrospective evaluation of the inclusion criteria for early
switch of the patients in the control phase would have been
insufﬁciently reliable and was therefore not performed.
The rate for switching patients with pneumonia to oral anti-
biotics was higher (42%), which was comparable to studies
where intervention was limited to patients with CAP.
11
Table 4. Statistical analysis of outcomes for the ﬁrst episode of antibiotic treatment
Outcomes
Control phase (1 April 2006 to
31 July 2006) all ﬁrst episodes
n¼162
Intervention phase (1 April 2007 to
31 July 2007)
P
value
b
all ﬁrst episodes
n¼215
switched episodes
a
n¼64
Number of days of iv antibiotic treatment per
patient, median (IQR)
6 (4–11) 5 (3.5–8.5) 3 (3–4) 0.005
Cumulative number of applications of iv
antibiotics per patient, median (IQR)
15 (8–26) 12 (6–23) 6.5 (4–9) 0.014
Number of days of subsequent oral antibiotic
treatment per patient, median (IQR)
0 (0–3) 1 (0–3) 3 (1.25–5.75) 0.228
Length of hospital stay per patient (days),
median (IQR)
13 (7–24) 12 (8–25) 9 (5–15) 0.873
Restarted iv antibiotic treatment per patient,
n (%)
overall during the same hospitalization 13 (8.0) 22 (10.2) 7 (11.1) 0.465
same diagnosis  5 days after stopping iv
antibiotic therapy
4 (2.5) 8 (3.7) 2 (3.1) 0.493
Complications of iv line per patient
c, n (%) 9 (5.6) 17 (7.9) 2 (3.1) 0.372
Deaths, n (%)
overall 13 (8.0) 15 (7.0) 1 (1.6) 0.701
due to the treated infections 3 (1.9) 8 (3.7) 0 (0.0) 0.286
Readmissions within 90 days, n (%)
overall 57 (35.2) 68 (31.6) 25 (39.1) 0.468
due to the treated infections 1 (0.6) 2 (0.9) 1 (1.6) 0.735
Primary antibiotic, n (%)
amoxicillin/clavulanate 66 (40.7) 75 (34.9) 31 (48.4) 0.245
ceftriaxone 35 (21.6) 57 (26.5) 21 (32.8) 0.272
piperacillin/tazobactam 29 (17.9) 58 (27.0)
d 7 (10.9) 0.863
cefepime 16 (9.9) 0 (0.0)
d 0 (0.0)
meropenem 6 (3.7) 9 (4.2) 1 (1.6) 0.813
IQR, interquartile range.
aOnly ﬁrst episodes which were switched on the third day of iv therapy.
bDifferences between groups using the Mann–Whitney U-test for non-categorical data and the x
2 test for categorical data comparing all ﬁrst episodes in the
control phase with the intervention phase.
cComplications of iv line: phlebitis, septic and non-septic thrombophlebitis.
dCefepime was not available on the Swiss market in 2007 and usually replaced by piperacillin/tazobactam.
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biotics was observed during the winter months (34.9%); this fact
emphasizes the importance of controlling for seasonal confound-
ing, which was not done in other studies (Table 1).
12,14,17,36
During the intervention phase, a reduction of the duration of iv
antibiotics was observed in most subgroups of infections.
Nevertheless, the reduction was signiﬁcant only in the subgroup
of lower respiratory tract infections, which may be due to the
low number of episodes in most other subgroups. As assumed,
there was no reduction in patients with endocarditis or infections
of bones or joints, as these patients need to be treated iv for a
certain time according to guidelines.
Safety of switching patients from iv to oral antibiotics
There was no signiﬁcant increase in patient relapse or hospital
readmissions during the intervention phase, and all infection-
related fatalities occurred in patients who were still being admi-
nistered iv antibiotics. A meta analysis by Rhew et al.
15 showed
that in terms of outcome in CAP, switching earlier to oral anti-
biotics was as effective as continued iv therapy. Therefore, the
British and American guidelines for the treatment of CAP
40,41
suggest switching early to oral therapy if possible. Comparable
results have also been observed for intra-abdominal infec-
tions,
42–44 anaerobic lung infection
45 and spontaneous bacterial
peritonitis.
29,46,47
Recently, some authors have recommended primary therapy
or switching to oral therapy in neutropenic patients
48–50 under
some conditions. Therefore, although it was not suggested by
the checklist, physicians also switched to oral antibiotics in 16
patients with neutropenia or haematological malignancies, with
successful outcomes.
Criteria against switching to oral antibiotics
Sevinc et al.
12 observed a persisting fever in 6% and neutropenia
in 1% of patients as the main reason against switching to oral
antibiotics; in our study, persisting fever and haematological
malignancies or neutropenia were more frequent (41.1% and
21.5%, respectively). This contrast highlights the relevance of
co-morbidities in patients, and how important the differences in
the case-mix of patients can be in evaluating the criteria for
switching to oral antibiotics.
Overall, of 246 cases that met all criteria on the checklist,
only 151 (61.1%) patients were switched to oral antibiotics. The
adherence to our checklist by physicians on the medical wards
increased over the duration of the intervention (from 48% to
68.7%), approaching the rate of general adherence to guidelines
in other Swiss hospitals (71%–75%).
51,52 If we had actively dis-
seminated the information to physicians, rather than having the
checklist available only with the patients’ chart, and had colla-
borated more closely with other specialists, the adherence rate
may have been even higher.
53 The increase in the rate of adher-
ence to the checklist criteria by physicians over time emphasizes
the relevance of information and teaching in order to rely on
switch criteria. In addition, many of the reasons presumed by
physicians as appropriate for not switching patients to oral anti-
biotics were incorrect, as was noted in other studies.
54,55 This
means that in addition to the printed guidelines themselves, con-
tinuing education is crucial.
56 The increase in ID consultations
at the beginning of the intervention was, perhaps, part of this
need for additional help and teaching. During the intervention
phase, there was no longer any statistically signiﬁcant increase,
and thus the reduction of iv treatment was not due to additional
ID consultations during the intervention phase.
A precise recommendation on how to switch from iv anti-
biotics with no direct oral equivalent formulation was not
offered. The decision was left to the discretion of the physician
in charge of the patients. Indeed, we found that patients
switched to oral antibiotics on day 3 were initially treated less
frequently by an iv formulation which was not available as an
oral formulation (e.g. piperacillin/tazobactam or meropenem).
This may indicate that, in general, less ill patients were more fre-
quently switched or alternatively, that the physicians in charge
were uncertain about which oral antibiotic they could switch
patients receiving antibiotics that were not available as an oral
formulation to. Consequently, one may speculate that the rate of
early switch may be increased by offering precise guidelines
regarding which oral antibiotics may be used in speciﬁc con-
ditions, or by an ID consultation.
In our study, the need for a physician to consult a clinical
pharmacist was rare; there were only 11 consultations in 698
cases (1.6%). Antibiotic stewardship programmes are mainly
conducted by ID specialists in Switzerland, in contrast to the
USA, where pharmacists can be specially trained in the ﬁeld
of ID.
Effect of switching to oral antibiotics on the workload and
antibiotic consumption
The number of hours required for administering iv antibiotics
was estimated to be reduced by 350 hours annually on the two
study wards. In contrast to studies optimizing antibiotic treat-
ment through consultations with ID specialists
57 and studies
using laboratory parameters to reduce the duration of antibiotic
therapy,
58 the implementation of the checklist does not generate
additional indirect costs. The checklist criteria may also be used
as part of a computerized decision support system with
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196integrated, automatic-reminder procedures,
28 which may be as
effective as the checklist chosen for this intervention.
The consumption of antibiotics overall in DDD per 100
patient-days was slightly, but not signiﬁcantly, increased in the
study year compared with the previous year. However, the costs
were reduced in part because of an increase in the consumption
of the cheaper oral application forms by 5%. For the most fre-
quently used antibiotic, amoxicillin/clavulanate, which is avail-
able in oral and iv application forms, the increase in the
consumption of the oral form was even more impressive
(10.9%). To exactly evaluate an intervention, the data must be
analysed at an individual level because the consumption at the
ward level is inﬂuenced by too many other factors, e.g. number
of patients in need of iv antibiotics.
Effect of switching to oral antibiotics on length
of hospital stay
Various studies have shown that an immediate discharge of the
patient from the hospital after stopping iv therapy can be
safe.
59–62 A reduction in the length of hospital stay is one of the
major areas of potential cost savings in using switch criteria;
63,64
this has been achieved for patients with lower respiratory tract
infections
63,65 or other types of infections.
64,66 However, like
Laing et al.,
14 we did not observe an overall reduction in length
of hospital stay despite an overall reduction in the duration of iv
antibiotic treatment in our study population. One explanation
may be the case-mix of patients, which required further diagnos-
tic workup or involved concomitant medical conditions, a possi-
bility corroborated elsewhere in the literature.
11,30,60,67
Limitations of the study
There was a difference in the number of observations in the
control and intervention phases, which reﬂects the usual ﬂuctu-
ation of the patient case-mix on general medical wards. It is
unlikely that this difference was due to the retrospective analysis
of the control phase, because all patients for this phase were
selected by using the same criteria that was used for the inter-
vention phase and the patient characteristics were similar in both
phases. A selection bias also is unlikely, because all patients
were consecutively screened for enrolment for the study.
The results of the intervention may have been less signiﬁcant
if the physicians from the study team had not also been present
sometimes on the wards and reminded the physicians in charge
of the wards to complete the forms when they forgot to do so.
Nevertheless, in most instances in which the checklist was not
completed on time and the criteria for switching the patient to
oral antibiotics were met, switching was performed before we
were able to remind the physician to complete the checklist.
The number of applications of antibiotics per day is inﬂu-
enced partly by what antibiotic is being used and by the renal
function in the patient. Therefore, the reduction in the cumulat-
ive number of antibiotic applications per patient does not
depend only on a reduction in duration of iv antibiotic treatment.
Nevertheless, there were no signiﬁcant differences noted over
time in the classes of antibiotics that were administered. The cal-
culation of the workload was an estimate and the precision is
therefore limited.
We used a before–after design, of which the main limitations
are regression to the mean and inadequate control for confound-
ing. The case-mix was comparable in both phases and we tried
to further minimize possible confounding effects by statistical
adjustment for possible confounders. A regression to the mean
may have inﬂuenced the drop of antibiotic costs. A causal
interpretation of the results is possible, bearing in mind that
other unknown or unmeasured confounders may exist that were
not accounted for in this study.
Strengths of the study
To assess the effect of our intervention, the two groups, control
and intervention phases, were analysed during the same months
in the year to avoid a seasonal bias. The observation period of
1 year was the longest, and the number of patients the highest,
of any study to date that has evaluated criteria for switching to
oral antibiotics on medical wards. In addition, we have collected
data on the safety of switching to oral treatment. Importantly,
we have included all patients in the study to evaluate the safety
of the checklist and have therefore not excluded patients who
are not eligible for an early switch, e.g. patients presenting with
infective endocarditis.
Further investigation of various issues may be performed in
the future. For example, the checklist may be used as an auto-
matic, computerized reminder if antibiotics are prescribed elec-
tronically. In addition, the checklist may be evaluated in other
patient populations, e.g. surgical patients. In our hospital, the
criteria have been implemented routinely since September 2008
on all Internal Medicine wards.
Conclusions
Our study shows that on general medical wards, a simple,
printed checklist with bedside criteria for switching from iv to
oral antibiotics can shorten the duration of iv therapy and reduce
treatment costs without any negative inﬂuence on the outcome
of treatment. The criteria were successfully applied to all
patients, independently of the indication (whether empirical or
treatment of documented infection), the type of (presumed)
infection, the underlying disease or the group of antibiotics
being used. The setting for our study represents daily medical
practice on a general hospital ward, without direct intervention
by ID specialists, thus making it possible to generalize the
results.
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